Pressure intensifies on top drug lobbyist to fix 'doughnut hole' issue
The pharmaceutical industry was dealt a significant blow on Thursday when a key provision impacting its payment obligations under the Medicare program was omitted from legislation to fund the Department of Health and Human Services. Drug companies rarely lose in Washington, and the latest defeat will intensify pressure on the industry’s top lobbying group at… Read More: Pressure intensifies on top drug lobbyist to fix 'doughnut hole'… »
